Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861106 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
A Phase 2 study of MDS and Immunodeficiency, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT01861106 is a Phase 2 study of MDS and Immunodeficiency that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 144 participants, above the 91-participant average among 22 other MDS trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01861106, a Phase 2 study of MDS and Immunodeficiency, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells from a matching donor (related or unrelated) to a recipient. It will allow the donor stem cells to produce healthy bone marrow and blood cells that will attack the recipient s cancer cells. Objectives: \- To see if stem cell transplants are successful at treating GATA2 mutations and related conditions. Eligibility: \- Recipients who are between 6 and 70 years of age and have GATA2 deficiency. Design: * All participants will be screened with a physical exam and medical history. Blood samples will be collected. Recipients will have imaging studies and other tests. * Recipients will have chemotherapy or radiation to prepare for the transplant. On the day of the transplant, they will receive the donated stem cells. * Recipients will stay in the hospital until their condition is stable after transplant. * Frequent blood tests and scans will be required for the first 6 months after the transplant, followed by less frequent visits over time.
Conditions Studied
Interventions
- PROCEDURE Allogeneic HSCT
- DRUG Busulfan Test dose
- DRUG Fludarabine (Fludara, Berlex Laboratories)
- DRUG Busulfan (Busulfex)
- DRUG Cyclophosphamide (CTX, Cytoxan)
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2013-07-24 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01861106
The ClinicalTrials.gov registry entry for NCT01861106 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 22 other MDS trials with a reported enrollment target (58% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with MDS appearing as the primary indexed condition, and to 5 interventions - of which Allogeneic HSCT is the first listed.
NCT01861106 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01861106 about?
NCT01861106 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations". Background: \- GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells from a matching donor (...
What is the current status of trial NCT01861106?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2013-07-24. Estimated completion is 2028-12-31.
What conditions does trial NCT01861106 study?
This clinical trial studies the following conditions: MDS, Immunodeficiency, GATA2.
What interventions are being tested in trial NCT01861106?
The interventions under investigation include: Allogeneic HSCT (PROCEDURE), Busulfan Test dose (DRUG), Fludarabine (Fludara, Berlex Laboratories) (DRUG), Busulfan (Busulfex) (DRUG), Cyclophosphamide (CTX, Cytoxan) (DRUG).
Who is sponsoring clinical trial NCT01861106?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01861106 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
-
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RECRUITING · Phase 2
-
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
RECRUITING · Phase 2
-
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
ACTIVE NOT RECRUITING · Phase 2
-
Allogeneic Transplantation From Related Haploidentical Donors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.